AVALIAÇÃO DA QUALIDADE MICROBIOLÓGICA DE FLORAIS DE BACH PRODUZIDOS NUMA FARMÁCIA DE MANIPULAÇÃO

Os remédios florais estão amplamente distribuídos pelo mundo e não apresentam efeitos colaterais ou riscos à saúde, sendo assim, indicados para todas as faixas etárias, bem como para  animais e plantas . O controle de qualidade microbiológico é um fator relevante a ser observado em florais, visto que estes não contém conservantes. Este estudo teve como objetivo avaliar a qualidade microbiológica dos Florais de Bach, além dos veículos água purificada e brandi 30%. Para tanto, foram elaboradas e avaliadas três amostras de cada um dos florais Rescue e buquê Medo, além do veículo Brandi 30% e da água purificada. Os ensaios foram realizados em triplicata para os tempos 0, 15, 30 e 60 dias. Para avaliação microbiológica realizou-se a diluição seriada de 1000 vezes, seguida de semeadura em meios de cultura para contagem de microrganismos mesófilos,  E. coli, Pseudomonas spp., Salmonella, S. aureus e determinação de fungos. Os resultados obtidos mostraram que os florais Rescue Remedy, buquê Medo e do brandi 30%, estão em acordo com os padrões estabelecidos pela Farmacopeia Brasileira, 5ª edição, no que se refere a contagem padrão de mesófilos totais (≤104 UFC/ml) e ausência de Pseudomonas sp., Salmonella sp. e S. aureus e E. coli, mesmo transcorridos 60 dias da elaboração. Já a água purificada exibiu desenvolvimento duas vezes maior, daquele preconizado pelo padrão, de microrganismos mesófilos ainda no tempo zero. Por conseguinte, estes dados são primordiais para a implementação da vigilância microbiológica nas preparações dos florais visando qualidade adequada dentro da validade

Antifungal activity of actinobacteria against fungus isolates of clinical importance

The escalating use of antifungal agents and long-term treatment approaches has led to an increased prevalence of fungus species that are resistant to the most common antifungal drugs. Actinobacteria produce a wide variety of bioactive secondary metabolites. This study investigated actinomycete isolates with the potential to produce bioactive compounds against dermatophyte fungus species and Candida spp. of clinical importance. Antifungal activity of actinomycetes was assessed using the double-layer agar technique. Active isolates were cultivated in starch casein broth (SCB) at 30 ºC for 8 days. Aliquots were retrieved at 24-h intervals and centrifuged to obtain extracts. Extract activity was assessed using the well-diffusion method. No dermatophyte fungus isolate was inhibited in the double-layer assay, although isolates 1S, R18(6) and 6(2) were active against all Candida spp. used in the assay. The well-diffusion method revealed that isolate R18(6) inhibited the six Candida spp. in a 72-h growth period in SCB broth, showing good potential to yield a compound with antifungal activity.(Atividade antifúngica de actinobactérias contra fungos isolados de importância clínica).O uso crescente de antifúngicos e os tratamentos prolongados vêm aumentando a incidência de fungos resistentes às drogas antifúngicas comumente utilizadas. As actinobactérias são conhecidas por produzirem uma grande variedade de metabólitos secundários bioativos e este trabalho teve como objetivo selecionar isolados de actinomicetos com potencial para produção de compostos bioativos contra fungos dermatófitos e espécies de Candida de importância clínica. A atividade antifúngica dos actinomicetos foi avaliada pela técnica da dupla camada. Os isolados que apresentaram atividade foram cultivados em caldo amido caseína (AC) à temperatura de 30 ºC por oito dias e foram retiradas e centrifugadas alíquotas a cada 24h, para obtenção do extrato. A atividade dos extratos foi avaliada através da técnica de difusão em poço. Nenhum dos isolados de fungos dermatófitos foi inibido no ensaio de dupla camada e os isolados 1S, R18(6) e 6(2) mostraram atividade frente todas as espécies de Candida testadas. No ensaio de difusão em poço com os extratos, o isolado R18(6) inibiu as seis espécies de Candida em 72h de crescimento em caldo AC e mostrou grande potencial para obtenção de composto com atividade antifúngica

A film-forming graphene/diketopyrrolopyrrole covalent hybrid with far-red optical features: Evidence of photo-stability

A dianiline derivative of a symmetric donor-acceptor-donor diketopyrrolopyrrole-based dye is employed for the two-sided covalent functionalization of liquid exfoliated few layers graphene flakes, through a direct arylation reaction. The resulting nanohybrid features the properties of a polymeric species, being solution-processed into homogeneous thin films, featuring a pronounced red-shift of the main absorption band with respect to the model dye unit and energy levels comparable to those of common diketopyrrolopyrrole-based polymers. A good electrical conductivity and the absence of radical signals generated after intense white light illumination, as probed through electron paramagnetic resonance, suggest a possible future application of this composite ma- terial in the field of photoprotective, antistatic layers with tunable colors

Draft genome sequences of six listeria monocytogenes strains isolated from dairy products from a processing plant in Southern Italy

Here we announce the draft genome sequences of 6 Listeria monocytogenes strains from ricotta cheese produced in a dairy processing plant located in southern Italy and potentially involved in a multistate outbreak of listeriosis in the United States

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy

Achievement of deep molecular response following treatment with a tyrosine kinase inhibitor (TKI) allows for treatment-free remission (TFR) in many patients with chronic myeloid leukemia (CML). Successful TFR is defined as the achievement of a sustained molecular response after cessation of ongoing TKI therapy. The phase 3 ENESTPath study was designed to determine the required optimal duration of consolidation treatment with the second-generation TKI, nilotinib 300 mg twice-daily, to remain in successful TFR without relapse after entering TFR for 12 months. The purpose of this Italian ‘patient’s voice CML’ substudy was to evaluate patients’ psycho-emotional characteristics and quality of life through their experiences of stopping treatment with nilotinib and entering TFR. The purpose of the present contribution is to early present the study protocol of an ongoing study to the scientific community, in order to describe the study rationale and to extensively present the study methodology. Patients aged ≥18 years with a confirmed diagnosis of Philadelphia chromosome positive BCR-ABL1+ CML in chronic phase and treated with front-line imatinib for a minimum of 24 months from the enrollment were eligible. Patients consenting to participate the substudy will have quality of life questionnaires and in-depth qualitative interviews conducted. The substudy will include both qualitative and quantitative design aspects to evaluate the psychological outcomes as assessed via patients’ emotional experience during and after stopping nilotinib therapy. Randomization is hypothesized to be a timepoint of higher psychological alert or distress when compared to consolidation and additionally any improvement in health-related quality of life (HRQoL) due to nilotinib treatment is expected across the timepoints (from consolidation, to randomization, and TFR). An association is also expected between dysfunctional coping strategies, such as detachments and certain personality traits, and psychological distress and HRQoL impairments. Better HRQoL outcomes are expected in TFR compared to the end of consolidation. This substudy is designed for in-depth assessment of all potential psycho-emotional variables and aims to determine the need for personalized patient care and counselling, and also guide clinicians to consider the psychological well-being of patients who are considering treatment termination. NCT number: NCT01743989, EudraCT number: 2012-005124-1

Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial

Background: The main objective of this study is to gain further insights on how chronic myeloid leukemia (CML) patients involved in an interventional clinical trial with the purpose of reaching treatment free remission (TFR) phase, perceived and experienced TFR failure. TFR failure was defined for the individual patient as either not being eligible for drug discontinuation or as having relapse in the TFR phase with reintroduction of nilotinib treatment. Methods: Using a qualitative approach, out of 25 patients with CML who experienced TFR failure 14 were interviewed. Patients' views and experiences were explored using in-depth interviews, analyzed using the Interpretative Phenomenological Analysis (IPA). Results: The analysis of the interviews revealed that the experience of the diagnosis seems to have been lived as a traumatic break that has created a dichotomy, like an ambivalence in the ways in which CML patients perceived and experienced the whole disease journey, with contradictory feelings of both positive and negative emotions (e.g., a diagnosis of cancer, that is something distressing and of being afraid of, but also with a treatment and a life expectancies of which being grateful). This ambivalence of feelings was found to give meaning to the way in which patients cognitively and emotionally experienced the different steps of their disease history. Thus, four main issues, corresponding to different steps of the patients' journey, were identified: (1) the moment of the diagnosis, (2) the experience of the illness journey: disease and treatment, (3) the moment of "TFR failure," and (4) the impact of disease, treatment and relapse on the patient's life. Conclusion: This qualitative analysis helps in understanding patients' perspective, both in terms of getting access to the inner subjective experience of having CML and its strict relationship with the involvement in a trial or its cessation. Clinicians should consider that the way in which CML patients feel engaged in a clinical trial, create expectancies about TFR or experience the TFR failure is linked to the process of coping with the diagnosis, which is characterized by ambivalence

The European Reference Genome Atlas: piloting a decentralised approach to equitable biodiversity genomics.

ABSTRACT: A global genome database of all of Earth’s species diversity could be a treasure trove of scientific discoveries. However, regardless of the major advances in genome sequencing technologies, only a tiny fraction of species have genomic information available. To contribute to a more complete planetary genomic database, scientists and institutions across the world have united under the Earth BioGenome Project (EBP), which plans to sequence and assemble high-quality reference genomes for all ∼1.5 million recognized eukaryotic species through a stepwise phased approach. As the initiative transitions into Phase II, where 150,000 species are to be sequenced in just four years, worldwide participation in the project will be fundamental to success. As the European node of the EBP, the European Reference Genome Atlas (ERGA) seeks to implement a new decentralised, accessible, equitable and inclusive model for producing high-quality reference genomes, which will inform EBP as it scales. To embark on this mission, ERGA launched a Pilot Project to establish a network across Europe to develop and test the first infrastructure of its kind for the coordinated and distributed reference genome production on 98 European eukaryotic species from sample providers across 33 European countries. Here we outline the process and challenges faced during the development of a pilot infrastructure for the production of reference genome resources, and explore the effectiveness of this approach in terms of high-quality reference genome production, considering also equity and inclusion. The outcomes and lessons learned during this pilot provide a solid foundation for ERGA while offering key learnings to other transnational and national genomic resource projects.info:eu-repo/semantics/publishedVersio

Potential of aqueous extracts of basidiomycetes to control root-knot nematodes on lettuce.

The root-knot nematode (Meloidogyne incognita) is one of the main pests of lettuce due to the crop?s high susceptibility, unavailability of registered nematicides and lack of resistant cultivars. The aim of this study was to evaluate the potential of aqueous extracts of ten basidiomycete fungi for root-knot nematodecontrol (in vitro and in vivo) on lettuce. The aqueous extracts of these fungi were initially evaluated in vitro in relation to their nematostatic and nematicidal activity. All extracts inhibited the hatching of second-stage juveniles of nematodes. The extracts that provided the highest mortality index (Pleurotus ostreatus, P. citrinopileatus, P. pulmonarius and Boletussp.) were applied in pots containing autoclaved and infested soil with root-knot nematode. After 24 h, one lettuce seedling (cv. Regina) per pot was transplanted using soil treated with distilled water as control. After 50 days, we observed that soil treated with fungal extracts reduced, approximately, 70% of nematode reproduction. Plants treated with extracts obtained higher fresh mass and extracts of Boletus sp. and P. pulmonarius reduced damages to roots, being considered as potential bio-controllers of this nematode.Made available in DSpace on 2019-12-20T18:10:55Z (GMT). No. of bitstreams: 1 18069991hb370154.pdf: 500505 bytes, checksum: 0fae6e9ff39fa04ba83123fce64d859c (MD5) Previous issue date: 2019bitstream/item/207681/1/1806-9991-hb-37-01-54.pd